Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review

OncoReview ◽  
2015 ◽  
Vol 5 (3) ◽  
pp. 117-121 ◽  
Author(s):  
Agnieszka Buraczewska ◽  
Joanna Kardas
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Interstitial Lung Disease ◽  
Literature Review ◽  
Lung Disease ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cell Carcinoma Case

scholarly journals Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report

2016 ◽  
Vol 2 (2-3) ◽  
pp. 69-70
Author(s):  
Bekir Muhammet Hacioglu ◽  
Osman Kostek ◽  
Bulent Erdogan ◽  
Hilmi Kodaz ◽  
Ilhan Hacibekiroglu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Durable Response ◽  
Renal Cell Carcinoma Case

Incidence and outcome of interstitial lung disease (ILD) with everolimus treatment for metastatic renal cell carcinoma.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 427-427
Author(s):  
Fumiya Hongo ◽  
Masakatsu Oishi ◽  
Takashi Ueda ◽  
Yasunori Kimura ◽  
Terukazu Nakamura ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Interstitial Lung Disease ◽  
Adverse Events ◽  
Lung Disease ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Intermediate Risk ◽  
Free Survival

427 Background: Interstitial lung disease (ILD) is known as one of the adverse events during treatment with everolimus for metastatic renal cell carcinoma (mRCC). Methods: We retrospectively assessed the incidence and outcome of ILD in mRCC patients treated with everolimus. From April 2010 to August 2012, 25 cases were treated with everolimus after failure of one or two TKIs in our institute. All adverse events were graded in accordance with NCI CTCAE, version 3.0. Results: A total of 25 patients received treatment with everolimus. They included 18 male and 7 female patients ranging in age from 21 to 84 years (median 62). According to MSKCC risk criteria, 6 cases were at favorable risk, 16 cases were at intermediate risk, and 3 cases were at poor risk. Median treatment term was 4 months (range 2-17 months). SD was in 19 cases and PD was in 6 cases. Progression free survival was 3.5 months and overall survival was 12 months. ILD was found in 7 cases (28%). 1 was G1, 5 were G2 and 1 was G3. Corticosteroid therapy was initiated in 3 cases. In 5 of 7 ILD cases, everolimus was re-challenged. In our series, patients with ILD showed significantly better progression free survival than those without ILD (PFS was 8 months vs. 3 months. Log-rank, p < 0.001). There were no significant different between the 2 groups in over all survival (12 months in patients with ILD vs. 10 months in patients without ILD. Log-rank, NS). Conclusions: Everolimus appears to be effective and well-tolerated in our institute. Re-challenge of everolimus was feasible after improving of everolimus-induced ILD in cases of grade 1-2.

Renal cell carcinoma: case report and literature review

2005 ◽  
Vol 40 (5) ◽  
pp. e13-e16 ◽  
Author(s):  
İbrahim Ötgün ◽  
Irfan Serdar Arda ◽  
Nihan Haberal ◽  
Hakan Güney ◽  
Akgün Hiçsönmez
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Literature Review ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cell Carcinoma Case

Regression of Metastatic Renal Cell Carcinoma: A Case Report and Literature Review

1986 ◽  
Vol 135 (5) ◽  
pp. 1005-1007 ◽  
Author(s):  
Louis R. Kavoussi ◽  
Sari R. Levine ◽  
Dov Kadmon ◽  
William R. Fair
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Literature Review ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals Metastatic Tfe3-Overexpressing Renal Cell Carcinoma: Case Report and Literature Review

2021 ◽  
Vol 8 (2) ◽  
Author(s):  
Ribeiro Paulo Victor Zattar ◽  
Pope Leonora Zozula Blind ◽  
Granelli Beatriz ◽  
Schulze Milena Luisa ◽  
Pires Andréa Rodrigues Cardovil ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Literature Review ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cell Carcinoma Case
Sign in / Sign up

Export Citation Format

Share Document